BridgeBio appoints Fred Hassan, Andrea Ellis, and Douglas Dachille to board of directors

BridgeBio Pharma, Inc.

Board expanded from 11 to 14 members; three new independent directors effective August 17, 2021.
Fred Hassan, former Schering-Plough CEO and Warburg Pincus director, appointed as Class II director.
Andrea Ellis, CFO of Lime and former Goldman Sachs banker, appointed as Class II director and audit committee member.
Douglas Dachille, former AIG CIO, appointed as Class III director; previously served as board observer.
Each director granted option to purchase $1.2M of common stock at $49.54, vesting over three years.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Fred Hassan

Director

BBIO · BridgeBio Pharma, Inc.

Effective: 2021-08-17
Filed: August 23, 2021, 7:59 PM ET

the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.

Appointed

Andrea Ellis

Director

BBIO · BridgeBio Pharma, Inc.

Effective: 2021-08-17
Filed: August 23, 2021, 7:59 PM ET

the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.

Appointed

Douglas Dachille

Director

BBIO · BridgeBio Pharma, Inc.

Effective: 2021-08-17
Filed: August 23, 2021, 7:59 PM ET

the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Fred Hassan was appointed as Director at BridgeBio Pharma, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrea Ellis was appointed as Director at BridgeBio Pharma, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Douglas Dachille was appointed as Director at BridgeBio Pharma, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.

View on SEC.gov

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-254149

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.